With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class.

ILC Therapeutics COO spoke with Manufacturing Chemist about how the Company is pioneering a novel drug class called hybrid interferons, Dawn Firmin, Chief Operating Officer.

Read the full article here: https://manufacturingchemist.com/hybrid-interferons-developing-a-novel-drug-class